Treatment of diabetes mellitus in a golden lion tamarin (Leontopithecus rosalia) with the glucagon-like peptide-1 mimetic exenatide

James G. Johnson, Jennifer N. Langan, Chen Gilor

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

An 8-yr-old male golden lion tamarin (Leontopithecus rosalia) was diagnosed with diabetes mellitus based on hyperglycemia and persistent glycosuria. Initial treatment consisted of the oral antihyperglycemic medications glipizide and metformin that resulted in decreased blood glucose concentrations; however, marked glycosuria persisted. Insufficient improvement on oral antihyperglycemic therapy and poor feasibility of daily subcutaneous insulin therapy led to an investigation into an alternative therapy with extended-release exenatide, a glucagon-like peptide-1 (GLP-1) mimetic, at a dosage of 0.13 mg/kg subcutaneously once per month. Following treatment with exenatide, the persistent glycosuria resolved, the animal maintained normal blood glucose concentrations, and had lower serum fructosamine concentrations compared to pretreatment levels. Based on these findings, extended-release exenatide could be considered as a therapeutic option in nonhuman primates with diabetes mellitus that do not respond to oral antihyperglycemics and in which daily subcutaneous insulin is not feasible.

Original languageEnglish (US)
Pages (from-to)903-906
Number of pages4
JournalJournal of Zoo and Wildlife Medicine
Volume47
Issue number3
DOIs
StatePublished - Sep 1 2016
Externally publishedYes

Fingerprint

Leontopithecus
glycosuria
Leontopithecus rosalia
hypoglycemic agents
glucagon-like peptide 1
Glucagon-Like Peptide 1
diabetes mellitus
mouth
Glycosuria
Diabetes Mellitus
blood glucose
Hypoglycemic Agents
glipizide
metformin
alternative medicine
therapeutics
hyperglycemia
Blood Glucose
drug therapy
Glipizide

Keywords

  • Callitrichid
  • diabetes mellitus
  • exenatide
  • glycosuria
  • golden lion tamarin
  • Leontopithecus rosalia

ASJC Scopus subject areas

  • Medicine(all)
  • Animal Science and Zoology
  • veterinary(all)

Cite this

Treatment of diabetes mellitus in a golden lion tamarin (Leontopithecus rosalia) with the glucagon-like peptide-1 mimetic exenatide. / Johnson, James G.; Langan, Jennifer N.; Gilor, Chen.

In: Journal of Zoo and Wildlife Medicine, Vol. 47, No. 3, 01.09.2016, p. 903-906.

Research output: Contribution to journalArticle

@article{23beb7f2ddf641218ff515da86aa4f1a,
title = "Treatment of diabetes mellitus in a golden lion tamarin (Leontopithecus rosalia) with the glucagon-like peptide-1 mimetic exenatide",
abstract = "An 8-yr-old male golden lion tamarin (Leontopithecus rosalia) was diagnosed with diabetes mellitus based on hyperglycemia and persistent glycosuria. Initial treatment consisted of the oral antihyperglycemic medications glipizide and metformin that resulted in decreased blood glucose concentrations; however, marked glycosuria persisted. Insufficient improvement on oral antihyperglycemic therapy and poor feasibility of daily subcutaneous insulin therapy led to an investigation into an alternative therapy with extended-release exenatide, a glucagon-like peptide-1 (GLP-1) mimetic, at a dosage of 0.13 mg/kg subcutaneously once per month. Following treatment with exenatide, the persistent glycosuria resolved, the animal maintained normal blood glucose concentrations, and had lower serum fructosamine concentrations compared to pretreatment levels. Based on these findings, extended-release exenatide could be considered as a therapeutic option in nonhuman primates with diabetes mellitus that do not respond to oral antihyperglycemics and in which daily subcutaneous insulin is not feasible.",
keywords = "Callitrichid, diabetes mellitus, exenatide, glycosuria, golden lion tamarin, Leontopithecus rosalia",
author = "Johnson, {James G.} and Langan, {Jennifer N.} and Chen Gilor",
year = "2016",
month = "9",
day = "1",
doi = "10.1638/2015-0270.1",
language = "English (US)",
volume = "47",
pages = "903--906",
journal = "Journal of Zoo and Wildlife Medicine",
issn = "1042-7260",
publisher = "American Association of Zoo Veterinarians",
number = "3",

}

TY - JOUR

T1 - Treatment of diabetes mellitus in a golden lion tamarin (Leontopithecus rosalia) with the glucagon-like peptide-1 mimetic exenatide

AU - Johnson, James G.

AU - Langan, Jennifer N.

AU - Gilor, Chen

PY - 2016/9/1

Y1 - 2016/9/1

N2 - An 8-yr-old male golden lion tamarin (Leontopithecus rosalia) was diagnosed with diabetes mellitus based on hyperglycemia and persistent glycosuria. Initial treatment consisted of the oral antihyperglycemic medications glipizide and metformin that resulted in decreased blood glucose concentrations; however, marked glycosuria persisted. Insufficient improvement on oral antihyperglycemic therapy and poor feasibility of daily subcutaneous insulin therapy led to an investigation into an alternative therapy with extended-release exenatide, a glucagon-like peptide-1 (GLP-1) mimetic, at a dosage of 0.13 mg/kg subcutaneously once per month. Following treatment with exenatide, the persistent glycosuria resolved, the animal maintained normal blood glucose concentrations, and had lower serum fructosamine concentrations compared to pretreatment levels. Based on these findings, extended-release exenatide could be considered as a therapeutic option in nonhuman primates with diabetes mellitus that do not respond to oral antihyperglycemics and in which daily subcutaneous insulin is not feasible.

AB - An 8-yr-old male golden lion tamarin (Leontopithecus rosalia) was diagnosed with diabetes mellitus based on hyperglycemia and persistent glycosuria. Initial treatment consisted of the oral antihyperglycemic medications glipizide and metformin that resulted in decreased blood glucose concentrations; however, marked glycosuria persisted. Insufficient improvement on oral antihyperglycemic therapy and poor feasibility of daily subcutaneous insulin therapy led to an investigation into an alternative therapy with extended-release exenatide, a glucagon-like peptide-1 (GLP-1) mimetic, at a dosage of 0.13 mg/kg subcutaneously once per month. Following treatment with exenatide, the persistent glycosuria resolved, the animal maintained normal blood glucose concentrations, and had lower serum fructosamine concentrations compared to pretreatment levels. Based on these findings, extended-release exenatide could be considered as a therapeutic option in nonhuman primates with diabetes mellitus that do not respond to oral antihyperglycemics and in which daily subcutaneous insulin is not feasible.

KW - Callitrichid

KW - diabetes mellitus

KW - exenatide

KW - glycosuria

KW - golden lion tamarin

KW - Leontopithecus rosalia

UR - http://www.scopus.com/inward/record.url?scp=84990184525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990184525&partnerID=8YFLogxK

U2 - 10.1638/2015-0270.1

DO - 10.1638/2015-0270.1

M3 - Article

VL - 47

SP - 903

EP - 906

JO - Journal of Zoo and Wildlife Medicine

JF - Journal of Zoo and Wildlife Medicine

SN - 1042-7260

IS - 3

ER -